- Home
- ATGE vs KNSA Comparison
ATGE vs KNSA Comparison
Compare ATGE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$95.11
HOLD
Current Price
$44.98
Company Overview
Basic Information| Metric | ATGE | KNSA |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.4B |
| IPO Year | 1991 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ATGE | KNSA |
|---|---|---|
| Price | $95.11 | $44.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $145.67 | $52.33 |
| AVG Volume (30 Days) | 495.1K | ★ 598.3K |
| Earning Date | 01-28-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.41 | N/A |
| EPS | ★ 6.76 | 0.47 |
| Revenue | ★ $1,888,834,000.00 | $597,973,000.00 |
| Revenue This Year | $9.99 | $62.99 |
| Revenue Next Year | $6.46 | $33.30 |
| P/E Ratio | ★ $14.92 | $95.77 |
| Revenue Growth | 11.92 | ★ 55.68 |
| 52 Week Low | $86.26 | $18.12 |
| 52 Week High | $156.26 | $45.50 |
Technical Indicators
Market Signals| Indicator | ATGE | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 32.36 | 58.64 |
| Support Level | $97.24 | $42.00 |
| Resistance Level | $104.28 | $45.01 |
| Average True Range (ATR) | 5.66 | 1.58 |
| MACD | -1.90 | 0.12 |
| Stochastic Oscillator | 0.81 | 80.25 |
Price Performance
Historical Comparison ATGE
KNSA
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.